Avon Q2 forecast
This article was originally published in The Rose Sheet
Executive SummaryDirect-seller reaffirms expectation that second quarter worldwide sales will rise approximately 4%, despite continued depressed results in Argentina, and that operating profits will increase by mid single-digits. In the U.S., sales predicted to advance 6%-7% in Q2 and operating profit to grow in low teens. For 2002, Avon predicting its third consecutive year of double-digit earnings growth. Firm is scheduled to report second quarter results July 19...
You may also be interested in...
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”